Illuminating Parathyroids with Fluorescence Imaging
Thursday, October 31 at 7:30 am CST
Cost: Free
Hypoparathyroidism remains the most frequent and serious long-term complication after thyroidectomy. New fluorescence-based techniques have developed rapidly over the last 10 years, enabling parathyroid glands to be better identified and preserved. This webinar will enable you to discover recent developments in these techniques and learn how you can incorporate them into your surgical practice.
This webinar is sponsored by Getinge.
FLUOBEAM LX is an imaging device configured for enhanced visualization of parathyroid glands during thyroid and parathyroid surgery, offering surgeons optimal control during use throughout the procedure. FLUOBEAM LX is the first imaging system FDA cleared and CE marked for autofluorescence of parathyroid glands during surgery.
dl-fluoptics-marketing@getinge.com
SPEAKERS
Frederic Triponez
Frédéric Triponez finished his medical school in Geneva in 1996. He completed his residency in general surgery in Geneva and then specialized in endocrine surgery, spending one year in Lille, France by prof C.A. Proye, and one year in San Francisco by prof O. Clark. When returning in Geneva in 2005, he developed the endocrine surgery unit, making it the biggest center for thyroid and parathyroid surgery in Switzerland.
He was appointed head of the department of Thoracic and Endocrine Surgery at the University Hospitals of Geneva in December 2013 and full professor of surgery at the Faculty of Medicine of Geneva. Since 2018, he is also chairman of the department of surgery.
His current areas of research relate to the development of innovative techniques to decrease the complication rate after thyroid surgery, including the use of neuromonitoring techniques and more recently the use of fluorescent techniques to help detect and protect the parathyroid glands, aiming at decreasing the rate of post-thyroidectomy hypoparathyroidism. He is one of the founding members and currently president of the ISITES (International Society of Innovative Technologies for Endocrine Surgery) and the leader of the annual symposium on parathyroid fluorescence (SPF) that will be organized for the 7th time in Barcelona in 2025.
Quan-Yang Duh
Quan-Yang Duh is UCSF's chief of endocrine surgery. He cares for patients with hormone gland tumors, including those of the thyroid, parathyroid and adrenal glands, as well as for patients with gastrointestinal cancers. He has a special interest in treating these disorders with laparoscopic and other minimally invasive procedures. He also supervises medical students, residents and fellows training at the San Francisco Veterans Affairs Medical Center.
Duh has published more than 400 papers and co-edited three textbooks. He serves on the editorial boards of numerous medical journals, including Thyroid, British Journal of Surgery, JAMA (Journal of the American Medical Association) Surgery, Journal of Clinical Endocrinology & Metabolism, Journal of the Endocrine Society and Asian Journal of Surgery. He has served as president of the American Association of Endocrine Surgeons and Pacific Coast Surgical Association, and he was the first vice president of the American College of Surgeons.
Duh earned his bachelor's degree in molecular biophysics and biochemistry at Yale University. He earned his medical degree at UCSF, where he also completed a residency in surgery and a fellowship in endocrine surgery.
